Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04973111 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose
A Phase 1 study of Diabetes, sponsored by Carmot Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT04973111 is a Phase 1 study of Diabetes that has completed, run by Carmot Therapeutics. The registered enrollment target is 32 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04973111, a Phase 1 study of Diabetes, has completed, sponsored by Carmot Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
A Study to Assess the Effect of CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose in Obese Male Subjects and Subjects with T2DM.
Conditions Studied
Interventions
- DRUG CT-868 as SC Injection
- DRUG Placebo as SC Injection
- DRUG Active Comparator as SC Injection
Study Locations (1)
California
- Carmot Clinical Research Unit 101 - Chula Vista
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2021-07-16 |
| Est. Completion | 2022-04-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04973111
The ClinicalTrials.gov registry entry for NCT04973111 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (99% lower). The listed sponsor is Carmot Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes appearing as the primary indexed condition, and to 3 interventions - of which CT-868 as SC Injection is the first listed.
NCT04973111 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04973111 about?
NCT04973111 is a clinical study titled "A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose". A Study to Assess the Effect of CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose in Obese Male Subjects and Subjects with T2DM.
What is the current status of trial NCT04973111?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2021-07-16. Estimated completion is 2022-04-22.
What conditions does trial NCT04973111 study?
This clinical trial studies the following conditions: Diabetes.
What interventions are being tested in trial NCT04973111?
The interventions under investigation include: CT-868 as SC Injection (DRUG), Placebo as SC Injection (DRUG), Active Comparator as SC Injection (DRUG).
Who is sponsoring clinical trial NCT04973111?
This trial is sponsored by Carmot Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04973111 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mitigating the Pro-inflammatory Phenotype of Obesity
RECRUITING · Phase 1
-
Pancreatic Islet Transplantation Into the Anterior Chamber of the Eye
RECRUITING · Phase 1
-
Insulin Balanced Infusion System
ACTIVE NOT RECRUITING · Phase 1
-
Ability of a Tea Leaf Extracts Preparation to Slow Down Carbohydrate and Fat Absorption
COMPLETED · Phase 1
-
Tissue Penetration of Ceftolozane/Tazobactam in Diabetic Patients With Lower Limb Infections
COMPLETED · Phase 1
-
Family Management of Childhood Diabetes Study
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.